A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome
暂无分享,去创建一个
M. Wulfsohn | M. Hirsch | T. Merigan | A. Tsiatis | C. Parker | D. Richman | C. Pettinelli | A. Collier | M. Fischl | E. Fuchs | R. Reichman | S. Rasheed | J. Gold | M. Ho | D. Antoniskis | N. H. Steigbigel | G. Leoung | M. Hirsch
[1] S W Lagakos,et al. Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection , 1990 .
[2] S. Lagakos,et al. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. , 1990, Journal of acquired immune deficiency syndromes.
[3] A. Collier,et al. Plasma viremia in human immunodeficiency virus infection. , 1989, The New England journal of medicine.
[4] D. Ho,et al. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1989, The New England journal of medicine.
[5] R. Schooley,et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. , 1989, JAMA.
[6] D. Richman,et al. The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker. , 1989, The Journal of infectious diseases.
[7] D. Richman,et al. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.
[8] D. Hawkins,et al. Zidovudine treatment of patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex: St Stephen's Hospital experience. , 1989, The Journal of infection.
[9] D. Jeffries,et al. Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex. , 1989, The Journal of infection.
[10] D. Mack,et al. Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT). , 1988, Annals of internal medicine.
[11] S. Larson,et al. Long‐term administration of 3′‐Azido‐2′,3′‐dideoxythymidine to patients with AIDS‐related neurological disease , 1988, Annals of neurology.
[12] M A Fischl,et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.
[13] M A Fischl,et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.
[14] D W Barry,et al. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[15] W. Grove. Statistical Methods for Rates and Proportions, 2nd ed , 1981 .
[16] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[17] J. Peto,et al. Asymptotically Efficient Rank Invariant Test Procedures , 1972 .
[18] H. B. Mann,et al. On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other , 1947 .